Axa reduced its position in Array Biopharma Inc (NASDAQ:ARRY) by 17.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 370,645 shares of the biopharmaceutical company’s stock after selling 80,986 shares during the quarter. Axa owned about 0.18% of Array Biopharma worth $4,744,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of ARRY. Point72 Asset Management L.P. lifted its holdings in shares of Array Biopharma by 274.4% during the third quarter. Point72 Asset Management L.P. now owns 9,008,999 shares of the biopharmaceutical company’s stock worth $110,811,000 after purchasing an additional 6,602,999 shares during the period. BlackRock Inc. lifted its holdings in shares of Array Biopharma by 12.6% during the fourth quarter. BlackRock Inc. now owns 15,252,802 shares of the biopharmaceutical company’s stock worth $195,236,000 after purchasing an additional 1,707,369 shares during the period. UBS Asset Management Americas Inc. lifted its holdings in shares of Array Biopharma by 172.9% during the fourth quarter. UBS Asset Management Americas Inc. now owns 2,112,438 shares of the biopharmaceutical company’s stock worth $27,039,000 after purchasing an additional 1,338,377 shares during the period. Eversept Partners LLC acquired a new stake in shares of Array Biopharma during the fourth quarter worth $15,844,000. Finally, 683 Capital Management LLC acquired a new stake in shares of Array Biopharma during the third quarter worth $6,150,000. 96.43% of the stock is owned by institutional investors and hedge funds.
In other Array Biopharma news, insider Victor Sandor sold 156,016 shares of the stock in a transaction on Friday, March 9th. The stock was sold at an average price of $17.71, for a total value of $2,763,043.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Andrew R. Robbins sold 282,874 shares of the stock in a transaction on Monday, December 18th. The stock was sold at an average price of $10.72, for a total value of $3,032,409.28. The disclosure for this sale can be found here. Insiders sold 1,359,061 shares of company stock valued at $16,292,205 in the last quarter. 3.18% of the stock is currently owned by company insiders.
Array Biopharma Inc (NASDAQ:ARRY) opened at $16.83 on Friday. The stock has a market capitalization of $3,652.33, a price-to-earnings ratio of -21.86 and a beta of 1.80. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.17 and a quick ratio of 6.17. Array Biopharma Inc has a 52-week low of $6.73 and a 52-week high of $18.78.
Array Biopharma (NASDAQ:ARRY) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. The firm had revenue of $42.21 million during the quarter, compared to analysts’ expectations of $26.81 million. Array Biopharma had a negative return on equity of 107.79% and a negative net margin of 98.51%. Array Biopharma’s revenue was down 5.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.14) earnings per share. equities analysts expect that Array Biopharma Inc will post -0.87 EPS for the current fiscal year.
About Array Biopharma
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).
Want to see what other hedge funds are holding ARRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Array Biopharma Inc (NASDAQ:ARRY).
Receive News & Ratings for Array Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.